Fluoxetine for stroke recovery: Meta-analysis of randomized controlled trials

International Journal of Stroke

Volumn 15, Issue 4, 2020, Pages 365-376

  Mead, Gillian E ^a   Legg, Lynn ^b   Tilney, Russel ^c   Hsieh, Cheng Fang ^d   Wu, Simiao ^e   Lundström, Erik ^f,g   Rudberg, Ann Sofie ^f,h   Kutlubaev, Mansur ^i,j   Dennis, Martin S ^k   Soleimani, Babak ^l   Barugh, Amanda ^l   Hackett, Maree L ^m,n,o   Hankey, Graeme J ^p  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

^c MATER DEI HOSPITAL   (Malta)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e SICHUAN UNIVERSITY   (China)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UPPSALA UNIVERSITY   (Sweden)

^h DANDERYD HOSPITAL   (Sweden)

ⁱ Kuvatov Republic Clinical Hospital   (Russian Federation)

^j BASHKIR STATE MEDICAL UNIVERSITY   (Russian Federation)

^k UNIVERSITY OF EDINBURGH   (United Kingdom)

^l NHS LOTHIAN   (United Kingdom)

^m UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁿ UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^o GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^p UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

fluoxetine; recovery; rehabilitation; Stroke

Indexed keywords

FLUOXETINE; PLACEBO;

ABDOMINAL PAIN; ANXIETY; CEREBROVASCULAR ACCIDENT; COGNITION; DEATH; DEPRESSION; DIARRHEA; DISABILITY; FATIGUE; FOLLOW UP; HEALTH CARE COST; HUMAN; INDEPENDENCE; MOTOR PERFORMANCE; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEIZURE; SYSTEMATIC REVIEW; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE REHABILITATION;

FATIGUE; FLUOXETINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; STROKE REHABILITATION;

EID: 85074517067     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1177/1747493019879655     Document Type: Review

References (32)

1. Johnson W, Onuma O, Owolabi M, Sachdev S. Stroke: a global response is needed. Bull World Health Organ 2016; 94: 634–634A.
2. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–602.
3. Yi ZM, Liu F, Zhai SD. Fluoxetine for the prophylaxis of post-stroke depression in patients with stroke: a meta-analysis. Int J Clin Prac 2010; 64: 1310–1317.
4. Chollet F, Tardy J, Albucher J-F, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10: 123–130.
5. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behaviour. Behav Pharmacol 2007; 18: 391–418.
6. Taupin P. Adult neurogenesis and neuroplasticity. Restor Neurol Neurosci 2006; 24: 9–15.
7. Loubinoux I, Boulanouar K, Ranjeva J-F, et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J Cereb Blood Flow Metab 1999; 19: 1365–1375.
8. Mead GE, Hsieh CF, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2012; 11: CD009286.
9. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 2018; 393: 265–274.
10. Higgins JPT and Green S (eds). Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration, www.handbook.cochrane.org (2011, accessed 27 September 2019)
11. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976; 54: 541–553.
12. Marquez-Romero JM, Arauz A, Ruiz-Sandoval JL, et al. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials 2013; 14: 77.
13. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.
14. Guo Y, He Y, Tang B, et al. Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. Restor Neurol Neurosci 2016; 34: 177–187.
15. He Y, Tang B, Cai Z, Zeng S, Jiang X, Guo Y. Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in China. J Stroke Cerebrovasc Dis 2016; 25: 761–770.
16. He Y, Cai Z, Zeng S, et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study. Clin Neurol Neurosurg 2018; 168: 1–6.
17. Zhao P, Wang JP. Effects of antidepressants on neurofunctional recovery of post – stroke patients with aphasia. J Dalian Med Univ 2011; 33: 55–57.
18. Birchenall J, Térémetz M, Roca P, et al. Individual recovery profiles of manual dexterity, and relation to corticospinal lesion load and excitability after stroke – a longitudinal pilot study. Neurophysiol Clin 2019; 49: 149–164.
19. Shah IA, Asimi RP, Kawoos Y, Wani MA, Wani MA, Dar MA. Effect of fluoxetine on motor recovery after acute haemorrhagic stroke: a randomized trial. J Neurol Neurophysiol 2016; 7: 364.
20. Dam M, Tonin P, De Boni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996; 27: 1211–1214.
21. He P. Randomized controlled observation on the effect of early application of fluoxetine in preventing depression after stroke. Chin J Clin Rehab 2004; 8: 6016–6017.
22. Kong Y. Fluoxetine for poststroke depression: a randomized placebo controlled clinical trial. Neural Regen Res 2007; 2: 162–165.
23. Li J, He Q-Y, Han M-F. Recent effect of fluoxetine in improving neurologic impairment and preventing post-stroke depression in the early stage. Chin J Postgrad Med 2004; 8: 1208–1209.
24. Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001; 50: 718–729.
25. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000; 157: 351–359.
26. Black-Schaffer R. Fluoxetine for motor, aphasia, and neglect recovery after ischemic stroke (FLAN) 2012, https://clinicaltrials.gov/ct2/show/NCT01674868 (accessed 25 September 2018)
27. Mikami K, Jorge RE, Adams HP, et al. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry 2011; 19: 1007–1015.
28. Gu SC, Wang CD. Early selective serotonin reuptake inhibitors for recovery after stroke: a meta-analysis and trial sequential analysis. J Stroke Cerebrovasc Dis 2018; 27: 1178–1189.
29. Adams HP, Jr Robinson RG. Improving recovery after stroke: a role for antidepressant medications?. Stroke 2012; 43: 2829–2832.
30. Chollet F. Selective serotonin reuptake inhibitors may be helpful in most patients with stroke. Stroke 2012; 43: 3150–3151.
31. Mead G, Hackett ML, Lundstrom E, Murray V, Hankey GJ, Dennis M. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. Trials 2015; 16: 369.
32. Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. Lancet 2014; 383: 156–165.